Anti-Mouse CD90 (Thy-1) (Clone HK2.1) – Purified in vivo GOLD™ Functional Grade
Anti-Mouse CD90 (Thy-1) (Clone HK2.1) – Purified in vivo GOLD™ Functional Grade
Product No.: C335
Clone HK2.1 Target CD90 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names Thy-1, CD90, CDw90 Isotype Rat IgG2c Applications FA , in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Rat IgG2c Recommended Dilution Buffer Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2829655 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone HK2.1 recognizes a non-polymorphic determinant on mouse CD90 (Thy1.1 and Thy1.2 alloantigens). Background CD90 is a 28-30 kD GPI-linked membrane glycoprotein and is part of the Ig superfamily. It interacts with CD45 in signal transduction. CD90 mediates adhesion of thymocytes to thymic stroma. It has been reported that CD90 binds with β2 and β3 integrins and is involved in the inhibition of hematopoietic stem cells proliferation and differentiation, as well as the regulation of cell adhesion and neurite outgrowth. It can be used as a marker for various stem cells, such as hematopoietic stem cells, and for the axonal processes of mature neurons. For use in FACS, CD90 is a popular surface marker for stem cells in combination with other markers such as CD34. There are two alleles for CD90 in mice that differ by one amino acid. The difference being that CD90.1 (Thy1.1) has an arginine and CD90.2 (Thy1.2) has a glutamine at position 108. CD90.2 is more prevalent and is expressed in most mice strains. CD90.1 is only expressed by a select few mice strains including AKR/J and PL strains. CD90.2 is a 25-35 kD GPI-anchored membrane glycoprotein. Like CD90, it is also in the Ig superfamily, interacts with CD45, and has involvement in signal transduction. The function of CD90.2 is thought to play roles in cognition, axon growth, T lymphocyte function, and apoptosis. CD90 acts as tumor suppressor for some tumors due to its action in upregulating thrombospondin, SPARC (osteonectin), and fibronectin. On the other hand, it has been suspected to aid in the spread of circulating melanoma cells. Regarding prostate cancer, CD90 has therapeutic potential for specific drug targeting due to its expression in cancer associated stroma, but not in normal stroma. Antigen Distribution CD90 is expressed by thymocytes, peripheral T cells, myoblasts, epidermal cells, and keratinocytes. Ligand/Receptor CD45 PubMed NCBI Gene Bank ID UniProt.org Research Area Immunology . Stem Cell Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Request failed: Based on the search results, the HK2.1 clone referenced appears to be an Anti-Mouse CD90 (Thy-1) Clone HK2.1 purified antibody product. Storage Temperature RequirementsFor the sterile packaged HK2.1 clone, the correct storage temperature is 2-8°C for short-term storage of up to one month. This temperature range is standard for functional grade preclinical antibodies when stored sterile as received. Extended Storage ConsiderationsWhile the search results mention that longer term storage options exist for this type of product, the specific temperature requirements for extended storage periods are not detailed in the available information. For optimal preservation of the sterile packaged clone's functionality and stability, maintaining the 2-8°C range is the established protocol for immediate use scenarios. The 2-8°C storage temperature ensures the sterile packaging maintains product integrity while preserving the biological activity of the HK2.1 clone antibody until it's ready for experimental use. Commonly used antibodies or proteins in the literature with HK2.1 (interpreted here as the canonical hexokinase 2 (HK2) antibody) often include markers involved in metabolism, stemness, cell signaling, and loading controls in Western blot and immunofluorescence studies. Frequently co-used primary antibodies and proteins include:
The pairing of HK2 with these antibodies often aims to:
If your context is a specific disease or experimental technique, marker selection may further include disease-relevant proteins or pathway components. The query seems to refer to "clone HK2.1," but there isn't specific information about it in the provided search results. However, I can provide some insights based on related topics:
If "clone HK2.1" refers to specific research in these areas, further details would be needed to provide more precise findings. However, the literature does highlight the importance of HK2 and hK2 in cancer biology, particularly in the context of metabolic alterations and potential therapeutic targets. References & Citations1. Ledbetter, J. A. et al. (1979) Immunol. Rev. 47:63
2. Ledbetter, J. A. et al. (1980) J. Exp. Med. 152:280
3. Lancki, D. W. et al. (1984) Immunol. Rev. 81:65 Technical ProtocolsCertificate of Analysis |
Related Products
Formats Available
Prod No. | Description |
---|---|
C1847 | |
C1849 | |
C279 | |
C1841 | |
C1842 | |
C1843 | |
C1845 | |
C282 | |
C335 | |
C280 | |
C635 | |
C281 | |
C302 |
